List view / Grid view
22 September 2017 | By IntelliCyt Corporation
In this webinar, Belen Ybarrondo, Ph.D and Thomas Duensing, Ph.D discuss the need for robust high content tools for current immunotherapeutic approaches, and how IntelliCyt's iQue Screener PLUS can give functional efficacy of immuno-oncology therapies...
Scientists have uncovered two closely related cytokines molecules involved in cell communication that explain why some people develop progressive MS...
In this application note IntelliCyt Corporation report on the development and validation of their family of MultiCyt QBeads for the detection of cytokines in a high-throughput screening application on the iQue Screener...
3 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Researchers found that A549-DR was resistant to the chemotherapeutic drug when transplanted in mice, while A549-DR with depleted IL-34 became sensitive...
Immune checkpoint inhibitory antibodies have provided a great conceptual change in the field of immune-oncology. Rather than targeting the tumour directly, these novel drugs are aimed at preventing the interactions between the tumour and the immune system, which the cancer exploits to evade immune recognition...
